Acute lung inflammation and acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), remain major clinical challenges with high morbidity and mortality. A key obstacle in drug development for these indications is the limited translational relevance of conventional rodent models.
Prisys Biotech has established a lipopolysaccharide (LPS)-induced Acute Lung Inflammation (ALI) model in cynomolgus monkeys, forming a core component of its Respiratory Disease (Respirology) Research Platform. This non-human primate (NHP) model is designed to closely recapitulate human pulmonary inflammatory responses and to support robust preclinical pharmacodynamic and biomarker-driven efficacy evaluation.
Model Overview
Model Name: LPS-Induced Acute Lung Inflammation / Acute Lung Injury Model in Cynomolgus Monkeys
Primary Purpose:
To simulate the inflammatory pathophysiology of human ALI/ARDS and evaluate the efficacy of anti-inflammatory, lung-protective, and regenerative therapies
Species: Cynomolgus monkey (Macaca fascicularis)
Translational Rationale:
Non-human primates exhibit high similarity to humans in lung anatomy, immune regulation, and inflammatory signaling pathways, providing superior predictive value compared with rodent models.
Model Induction Methodology
Precise Bronchoscopic Administration
Induction Agent: Lipopolysaccharide (LPS)
Route of Administration: Bronchoscopic instillation into predefined lung lobes
Targeted Induction:
Typically limited to selected lobes (e.g., left lower lobe or right lower lobe), enabling a localized lung injury model while preserving internal controls in non-treated lobes (commonly described as a "3/4 lung involvement" configuration).
Dynamic Dose Adjustment Strategy
Initial Dose: Escalating daily dose per lung lobe
Dose Modulation:
LPS dosage is dynamically increased or decreased based on daily chest CT findings, allowing precise control of injury severity and inflammatory burden.
Study Duration:
A typical pilot or pharmacology study spans 7 days, with continuous monitoring throughout the induction phase.
This adjustable design enables modeling of different severities of lung inflammation, supporting graded pharmacodynamic evaluation.
Comprehensive Evaluation and Readout System
The ALI NHP model incorporates a multi-dimensional assessment framework, ensuring robust and reproducible data generation.
Imaging Assessment
Chest CT (non-contrast):
Performed prior to induction and daily post-induction
Enables longitudinal visualization of pulmonary inflammation, consolidation, and exudative changes
Bronchoalveolar Lavage Fluid (BALF) Analysis
Sampling: Daily BALF collection from the target lung lobe
Cellular Analysis:
Total cell counts and differential counts
Quantification of macrophages and neutrophils
Marked increase in neutrophil proportion following LPS challenge
Cytokine Profiling:
Measurement of pro-inflammatory mediators (e.g., IL-6) in BALF supernatant using ELISA or equivalent assays
Key Advantages of the Prisys ALI NHP Model
High Translational Relevance: Use of non-human primates bridges the gap between preclinical and clinical outcomes.
Standardized and Reproducible: Bronchoscopic delivery ensures precise localization and consistent injury induction.
Dynamically Controllable Severity: CT-guided dose adjustment allows flexible modeling of mild to severe lung inflammation.
Multi-Level Readouts: Integrated imaging, physiological, cellular, and molecular endpoints provide a comprehensive view of lung injury and therapeutic response.
Applications in Drug Development
The LPS-induced ALI NHP model is well suited for evaluating:
- Small-Molecule Anti-Inflammatory Agents: Assessment of neutrophil infiltration, cytokine suppression, and systemic inflammatory markers.
- Biologics and Targeted Therapies: Including anti-cytokine antibodies and pathway-specific inhibitors.
- Lung-Protective and Regenerative Therapies: Evaluation of pulmonary edema reduction and alveolar epithelial repair.
- Novel Pulmonary Drug Delivery Systems: Characterization of lung-targeted distribution and local efficacy.
Compared with rodent ALI models, data generated from this NHP platform provide higher confidence in clinical translation, helping to reduce late-stage development risk.
Integrated Platform Support at Prisys Biotech
Prisys Biotech's Shanghai R&D Center is fully equipped to support ALI NHP studies, including:
- Bronchoscopy systems
- Dedicated animal CT imaging platforms
- Pulmonary function testing equipment
- Biosafety laboratories
- Experienced veterinary, surgical, and technical teams
From animal training and model induction to sample analysis and data interpretation, Prisys delivers end-to-end, high-quality execution under standardized and welfare-compliant conditions.
Conclusion
The LPS-induced Acute Lung Inflammation model in cynomolgus monkeys developed by Prisys Biotech represents a rigorous, controllable, and highly translational preclinical platform for respiratory drug development. By combining precise induction, dynamic severity control, and comprehensive multi-level assessments, this model provides researchers with reliable pharmacodynamic and biomarker data to support confident progression into clinical development.
